This study is testing a combination of three existing medications (metformin, simvastatin, and digoxin, together called C3) with or without Gemcitabine for people with advanced pancreatic cancer that has returned or gotten worse after standard treatments. The main goals are to see if this combination is safe and tolerable, and if it helps reduce the cancer or prolong life. You might be eligible if you are at least 18 years old, have pancreatic cancer that has progressed, and have an ECOG performance status of 0-1 (meaning you are fully active or can perform light work). Researchers will also look at a protein level (BIRC5) from a past biopsy. The study aims to enroll 25 participants, but its current status is unclear.

Study design

This is an open-label, single-center, phase 2 feasibility trial. It will involve 25 participants and is not blinded, meaning both you and the study team will know which treatment you are receiving.

What's involved

Participants will receive metformin, digoxin, and simvastatin (C3) for up to 2 years. If you agree, you will also receive Gemcitabine according to standard care.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of safety and tolerability will be measured at 28 days after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.